Beyond 2013 CEE Drug Market Outlook ImprovesAugust 2012 | Industry Trend Analysis
BMI View: The Pharmaceutical & Healthcare team have long said that 2012 will be a particularly difficult year for drugmakers operating in Central And Eastern Europe. Company financial results for the first half of the year have strongly supported this view, and we continue to expect austerity and weaker economic growth to limit growth potential into 2013. However, beyond 2013 we are expecting stronger growth across the region. Together, the region's markets will post considerably stronger growth than those in Western Europe, where pharmaceutical markets will continue to stagnate. The reasons for this outperformance are many, and the primary drivers of growth vary across this heterogeneous region.
To read the full article, please choose one of the following options: